Egashira Ayaka, Yanagihara Toyoshi, Ogo Naruhiko, Asoh Tatsuma, Maeyama Takashige
Department of Respiratory Medicine, Hamanomachi Hospital, Fukuoka, JPN.
Cureus. 2021 Dec 25;13(12):e20676. doi: 10.7759/cureus.20676. eCollection 2021 Dec.
We report a case of drug-induced interstitial lung disease (ILD) caused by epirubicin and cyclophosphamide (EC) therapy in a patient with breast cancer. The patient suffered from a dry cough, fever, and exertional dyspnea after two courses of EC therapy. Antibiotic treatment did not improve her symptoms. Chest CT images revealed diffuse, ground-glass opacities and mild interlobular septal thickening in both lungs, a pattern suggesting a hypersensitivity pneumonitis. Bronchoalveolar lavage fluid analysis revealed lymphocytosis with no evidence of infection nor malignancy. Corticosteroid therapy was initiated, which led to a rapid resolution of ILD. To date, there has been only one case report regarding drug-induced ILD caused by EC therapy. This case report could increase awareness of chemotherapy-induced pneumonitis.
我们报告了1例乳腺癌患者在接受表柔比星和环磷酰胺（EC）治疗后发生药物性间质性肺病（ILD）的病例。该患者在接受两个疗程的EC治疗后出现干咳、发热和劳力性呼吸困难。抗生素治疗未能改善其症状。胸部CT图像显示双肺弥漫性磨玻璃影和轻度小叶间隔增厚，这种表现提示为过敏性肺炎。支气管肺泡灌洗 fluid分析显示淋巴细胞增多，未发现感染或恶性肿瘤的证据。开始使用皮质类固醇治疗，ILD迅速得到缓解。迄今为止，关于EC治疗引起的药物性ILD仅有1例病例报告。本病例报告可提高对化疗引起的肺炎的认识。
